These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6835327)

  • 1. Maple-syrup-urine disease.
    Wendel U; Lombeck I; Bremer HJ
    N Engl J Med; 1983 May; 308(18):1100-1. PubMed ID: 6835327
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective study of maple-syrup-urine disease for the first four days of life.
    DiGeorge AM; Rezvani I; Garibaldi LR; Schwartz M
    N Engl J Med; 1982 Dec; 307(24):1492-5. PubMed ID: 7144815
    [No Abstract]   [Full Text] [Related]  

  • 3. Branched-chain alpha-keto acids for the diagnosis of maple-syrup-urine disease.
    Parsons H; Fung E; Snyder FF
    N Engl J Med; 1987 Apr; 316(15):951. PubMed ID: 3821846
    [No Abstract]   [Full Text] [Related]  

  • 4. Neonatal screening for maple syrup urine disease by an enzyme-mediated colorimetric method.
    Wendel U; Gonzales J; Hummel W
    Clin Chim Acta; 1993 Oct; 219(1-2):105-11. PubMed ID: 8306450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between branched-chain amino acids and branched-chain alpha-keto acids in blood in maple syrup urine disease.
    Langenbeck U; Wendel U; Mench-Hoinowski A; Kuschel D; Becker K; Przyrembel H; Bremer HJ
    Clin Chim Acta; 1978 Sep; 88(2):283-91. PubMed ID: 699323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between the branched chain amino acids and their alpha-ketoacids in maple syrup urine disease.
    Snyderman SE; Goldstein F; Sansaricq C; Norton PM
    Pediatr Res; 1984 Sep; 18(9):851-3. PubMed ID: 6483508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nasogastric drip feeding as the only treatment of neonatal maple syrup urine disease.
    Parini R; Sereni LP; Bagozzi DC; Corbetta C; Rabier D; Narcy C; Hubert P; Saudubray JM
    Pediatrics; 1993 Aug; 92(2):280-3. PubMed ID: 8337030
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection of maple syrup urine disease on resin coated chromatosheets.
    Kovács J
    Acta Biochim Biophys Acad Sci Hung; 1979; 14(3):119-21. PubMed ID: 547666
    [No Abstract]   [Full Text] [Related]  

  • 9. Implications of Maple Syrup Urine Disease in Newborns.
    Harris-Haman P; Brown L; Massey S; Ramamoorthy S
    Nurs Womens Health; 2017; 21(3):196-206. PubMed ID: 28599741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental profile of patients with maple syrup urine disease.
    Nord A; van Doorninck WJ; Greene C
    J Inherit Metab Dis; 1991; 14(6):881-9. PubMed ID: 1723442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of branched-chain amino acids in blood spots and plasma by liquid chromatography tandem mass spectrometry for the diagnosis of maple syrup urine disease.
    Sowell J; Pollard L; Wood T
    J Sep Sci; 2011 Mar; 34(6):631-9. PubMed ID: 21328532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and treatment of maple syrup disease: a study of 36 patients.
    Morton DH; Strauss KA; Robinson DL; Puffenberger EG; Kelley RI
    Pediatrics; 2002 Jun; 109(6):999-1008. PubMed ID: 12042535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of dried blood spot monitoring of branched-chain amino acids for maple syrup urine disease: A retrospective chart review study.
    Kaur J; Nagy L; Wan B; Saleh H; Schulze A; Raiman J; Inbar-Feigenberg M
    Clin Chim Acta; 2020 Jan; 500():195-201. PubMed ID: 31678570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI in acute intermittent maple syrup urine disease.
    Di Rocco M; Biancheri R; Rossi A; Allegri AE; Vecchi V; Tortori-Donati P
    Neurology; 2004 Sep; 63(6):1078. PubMed ID: 15452301
    [No Abstract]   [Full Text] [Related]  

  • 15. Maple syrup urine disease: interrelations between branched-chain amino-, oxo- and hydroxyacids; implications for treatment; associations with CNS dysmyelination.
    Treacy E; Clow CL; Reade TR; Chitayat D; Mamer OA; Scriver CR
    J Inherit Metab Dis; 1992; 15(1):121-35. PubMed ID: 1583867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In response to R.E. Roux et al (2006) the longest surviving patient with classical maple syrup urine disease. J Inherit Metab Dis 29:190-194.
    Snyderman SE
    J Inherit Metab Dis; 2006 Oct; 29(5):690. PubMed ID: 16924399
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnosis of MSUD by newborn screening allows early intervention without extraneous detoxification.
    Heldt K; Schwahn B; Marquardt I; Grotzke M; Wendel U
    Mol Genet Metab; 2005 Apr; 84(4):313-6. PubMed ID: 15781191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The longest-surviving patient with classical maple syrup urine disease.
    le Roux C; Murphy E; Lilburn M; Lee PJ
    J Inherit Metab Dis; 2006 Feb; 29(1):190-4. PubMed ID: 16601890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-tier test for quantification of alloisoleucine and branched-chain amino acids in dried blood spots to improve newborn screening for maple syrup urine disease (MSUD).
    Oglesbee D; Sanders KA; Lacey JM; Magera MJ; Casetta B; Strauss KA; Tortorelli S; Rinaldo P; Matern D
    Clin Chem; 2008 Mar; 54(3):542-9. PubMed ID: 18178665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maple syrup urine disease variant form: presentation with psychomotor retardation and CT scan abnormalities.
    Verdu A; Lopez-Herce J; Pascual-Castroviejo I; Martinez-Bermejo A; Ugarte M; Garcia MJ
    Acta Paediatr Scand; 1985 Sep; 74(5):815-8. PubMed ID: 4050430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.